Presently, the primary treatment for T2DM is pharmacotherapy, which includes GLP1 modulators, Thiazolidinedione insulin sensitizers, and SGLT2 inhibitors, among others [23]. Here, SLC5A2 is linked to type 2 diabetes mellitus.